-I F Mckenzie Researcher Activity Profile

Research Author Detailed Information 

I F Mckenzie Publication Rate By Year

I F Mckenzie has published 2 paper(s) in 1993, 2 paper(s) in 1994, 1 paper(s) in 1995, 1 paper(s) in 1996, 1 paper(s) in 1997, 3 paper(s) in 2000, 2 paper(s) in 2001, 3 paper(s) in 2007, for a total of 15 research publications in total.

I F If Mckenzie Author Information

LAST NAME: mckenzie

FIRST NAME: I F

INITIALS: if

AFFILIATION:

Papers

I F Mckenzie's Publication Record

1. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Year Published: 2000
The Austin Research Institute, Studley Rd, Heidelberg, Australia. g.pietersz@ari.unimelb.edu.au
2. Monoclonal antibodies to mucin VNTR peptides. Year Published: 2000
Austin Research Institute, Austin and Repatriation Medical Centre, Heidelberg, Australia.
3. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Year Published: 2000
The Austin Research Institute, Heidelberg, Australia. v.apostolopoulos@ari.unimelb.edu.au
4. Breast cancer in mice: effect of murine MUC-1 immunization on tumor incidence in C3H/HeOuj mice. Year Published: 2001
The Austin Research Institute, Austin and Repatriation Medical Center, Heidelberg, Victoria, Australia.
5. MUC1 and breast cancer. Year Published: 2001
Austin Research Institute, Austin and Repatriation Medical Center, Studley Road, Heidelberg, VIC 3084, Australia. v.apostolopoulos@ari.unimelb.edu.au
6. Expression of MUC1 and MUC2 mucins by human tumor cell lines. Year Published: 1993
Medical Innovations Limited, Labrador, Australia.
7. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Year Published: 1993
Department of Pathology, Kagoshima University School of Medicine, Japan.
8. Peptide binding sites recognized by anti-mucin (MUC2) monoclonal antibodies. Year Published: 1994
Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia.
9. Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Year Published: 1994
10. Peptide epitopes in breast cancer mucins. Year Published: 1995
Austin Research Institute, Austin Hospital, Heidelberg, Vic., Australia.
11. Anti-peptide monoclonal antibodies to intestinal mucin 3. Year Published: 1996
Austin Research Institute, Heidelberg, Victoria, Australia.
12. Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides. Year Published: 1997
Austin Research Institute, Austin & Repatriation Medical Centre, Heidelberg, Vic, Australia.
13. Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Year Published: 2007
1Department of Surgery (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia.
14. Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Year Published: 2007
Department of Surgery (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia.
15. Carbohydrate residues downstream of the terminal Galalpha(1,3)Gal epitope modulate the specificity of xenoreactive antibodies. Year Published: 2007
Department of Surgery (Austin Health), University of Melbourne, Heidelberg, Victoria, Australia.